comparative between butorphanol and nalbuphine as to adjuvants to spinal bupivacaine in infra umbilical surgeries
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: K409- Unilateral inguinal hernia, without obstruction or gangrene
- Registration Number
- CTRI/2019/04/018408
- Lead Sponsor
- Yawanth Reddy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients posted for lower abdominal, lower limb surgeries under spinal anaesthesia
Exclusion Criteria
Patients allergic to local anaesthetics, nalbuphine/ Butorphanol
ASA physical status III or more
Height <140cms and BMI >30 kg/m2
Patient contraindicated for spinal anaesthesia
Patient who had acute and chronic pain elements
Patient refusal
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the duration of analgesia in terms of time to first analgesic requirement. <br/ ><br>Timepoint: Postoperatively <br/ ><br>
- Secondary Outcome Measures
Name Time Method To compare quality of analgesia measured in terms of total analgesic requirement . <br/ ><br> <br/ ><br>To compare pain scores, duration of motor blockade, perioperative hemodynamic parameters. <br/ ><br> <br/ ><br>To study the incidence of opioid related side effects in the two groups <br/ ><br>Timepoint: intra operatively and Postoperatively
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of butorphanol and nalbuphine as adjuvants to intrathecal bupivacaine in unilateral inguinal hernia surgery?
How does the effectiveness of butorphanol compare to nalbuphine as adjuvants to spinal bupivacaine in infra umbilical surgeries?
What biomarkers are associated with optimal patient selection for butorphanol or nalbuphine adjuvant therapy in hernia repair?
What are the potential adverse events and management strategies for butorphanol or nalbuphine in spinal anesthesia for unilateral inguinal hernia?
Are there related compounds or combination approaches that enhance the analgesic effects of butorphanol or nalbuphine in hernia surgery?